Peer-reviewed veterinary case report
Liposomal bupivacaine does not raise infection risk after dog and cat
By Andrews, Camille et al.·Published in Journal of the American Veterinary Medical Association·2024·University of Florida, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Use of liposomal bupivacaine in dogs and cats undergoing gastrointestinal surgery is not associated with a higher rate of surgical site infections or multidrug-resistant infections.
- Species:
- dog
Plain-English summary
A study looked at dogs and cats that had gastrointestinal surgery to see if using a pain medication called Nocita would affect the chance of developing surgical site infections (SSIs). Among the dogs, 5.6% who received Nocita developed an SSI, compared to 10.2% who did not. For cats, the rates were similar, with 3.6% of those receiving Nocita and 4% not receiving it developing an SSI. The findings suggest that using Nocita does not increase the risk of infections after surgery, even in dogs with pre-existing infections.
People also search for: dog surgery infection risk · cat gastrointestinal surgery recovery · Nocita pain medication for pets
Abstract
OBJECTIVE: To report the rate of surgical site infections (SSIs) after clean-contaminated and dirty gastrointestinal surgery in dogs and cats that did and did not receive incisional infiltration of Nocita and report the bacteria isolated. ANIMALS: Client-owned dogs (n = 211) and cats (78). METHODS: Records of dogs and cats that underwent gastrointestinal surgery at the Matthew J. Ryan Veterinary Hospital of the University of Pennsylvania and the University of Florida Small Animal Hospital between July 1, 2020, and April 1, 2023, were reviewed for surgical procedures, presence of preoperative septic peritonitis, use of Nocita, perioperative antibiotics administered, postoperative antibiotic use, SSI development postoperatively, and aerobic bacteria isolated. RESULTS: 7 of 124 (5.6%) dogs that received Nocita and 9 of 87 (10.2%) that did not receive Nocita developed an SSI. No dogs presenting with septic peritonitis and given Nocita (n = 5) developed an SSI. Two of 55 (3.6%) cats that received Nocita and 1 of 23 (4%) that did not receive Nocita developed an SSI. Multidrug-resistant (MDR) Escherichia coli was the most common aerobic bacteria isolated from SSIs (n = 3), and MDR bacteria were isolated commonly from both groups (4). CLINICAL RELEVANCE: Use of Nocita for gastrointestinal surgery in dogs and cats is not associated with higher rates of SSI than published rates of SSI after gastrointestinal surgery. Use of Nocita in dogs with preoperative septic peritonitis is not associated with the development of SSI. MDR bacteria are commonly isolated via culture from both dogs that received Nocita and those that did not.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/37918106/